This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current Drug Targets. 2018; 19(1):38-54.Search in Google Scholar
Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 2010; 69(3):222-230.Search in Google Scholar
Zhao M, Ma J, Li M et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci. 2021; 22(23):12808.Search in Google Scholar
Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2004; 369(1):89-104.Search in Google Scholar
Dorji PW, Tshering G, Na-Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. J Clin Pharm Ther. 2019; 44:508-524Search in Google Scholar
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2):229-243.Search in Google Scholar
Hassani Idrissi H, Hmimech W, Khorb NE, et al. A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. BMC Research Notes. 2018; 11(1):46.Search in Google Scholar
Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J. Pers. Med. 2018; 8(1):8.Search in Google Scholar
Riaz S, Muhammad Din S, Usman Tareen M, et al. Genetic Polymorphism of CYP2C19 in Pakistani Population. Iran J Pharm Res. 2019; 18(2):1097-1102.Search in Google Scholar
Ivanov HY, Grigorova D, Lauschke VM, et al. CYP2C19, and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort. J Pers Med. 2022 Jul 21; 12(7):1187Search in Google Scholar
Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000; 10(6):567-570.Search in Google Scholar
Mo SL, Liu YH, Duan W, et al. Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6. Current Drug Metabolism. 2009; 10(7):730-753.Search in Google Scholar
Langmia IM, Just KS, Yamoune S, et al. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations – Implication for Drug Safety, Dosing, and Individualized Therapy. Frontiers in Genetics. 2021; 12.Search in Google Scholar
Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics. 2005; 15(1):1-5.Search in Google Scholar
Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol 2013; 69(11):1909-1916.Search in Google Scholar
Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics. 2013; 4.Search in Google Scholar
Victorri-Vigneau C, Verstuyft C, Bouquié R, et al. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharma-cokinetics and response in the OPAL study. Br J Clin Pharmacol 2019; 85(7):1538-1543.Search in Google Scholar
Chiang YC, Wang RY, Huang CL, et al. Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. J Cell Mol Med. 2017; 21(12):3552-3564.Search in Google Scholar
Aghabozorg Afjeh SS, Boshehri B, Hamednia S, et al. Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. Iranian Biomedical Journal. 2021; 25(3):220-225.Search in Google Scholar
Kharasch ED, Regina KJ, Blood J, et al. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015; 123(5):1142-1153.Search in Google Scholar
Dean L, Kane M. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 [updated 2022 Dec 1]. In: Pratt VM, Scott SA, Pirmohamed M, et al. editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012Search in Google Scholar
Alrajeh KY, Roman YM. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Personalized Medicine. 2022; 19(4):327-339.Search in Google Scholar
Shuldiner AR, O‘Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26; 302(8):849-857Search in Google Scholar
Wang B, Wang J, Huang SQ, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Current Drug Metabolism. 2009; 10(7):781-834.Search in Google Scholar
